Preliminary results from the late-stage human trial of Russia’s main coronavirus vaccine candidate could include data from 5,000-10,000 participants, Denis Logunov, a director at the Gamaleya Institute that developed the vaccine, has said.
Russia’s plan to publish preliminary data about the Sputnik V jab as early as November is likely to make it one of the first vaccine developers to share any data from a final stage trial, known as phase 3, but also puts it at odds with competitors.
The Sputnik V trial, involving 40,000 volunteers, has been underway in Moscow since the beginning of September.
